| 41.02 0.62 (1.53%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 49.28 | 1-year : | 51.38 |
| Resists | First : | 42.19 | Second : | 43.99 |
| Pivot price | 41.18  |
|||
| Supports | First : | 39.29 | Second : | 32.68 |
| MAs | MA(5) : | 40.01 |
MA(20) : | 41.55 |
| MA(100) : | 40.1 |
MA(250) : | 40.43 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 22.6 |
D(3) : | 13.2 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 50.2 | Low : | 31.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BAX ] has closed above bottom band by 47.0%. Bollinger Bands are 67.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 41.22 - 41.39 | 41.39 - 41.55 |
| Low: | 39.84 - 40.02 | 40.02 - 40.2 |
| Close: | 40.72 - 41.01 | 41.01 - 41.29 |
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Wed, 24 Apr 2024
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Baxter International Inc. Investors with Losses to Secure ... - The Globe and Mail
Tue, 23 Apr 2024
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Tue, 23 Apr 2024
Baxter (BAX) Beats on Q1 Earnings and Revenue Estimates - Yahoo Movies Canada
Mon, 22 Apr 2024
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Sun, 21 Apr 2024
Baxter International Inc. (NYSE:BAX) Shares Sold by Cooke & Bieler LP - MarketBeat
Sat, 20 Apr 2024
There's A Lot To Like About Baxter International's (NYSE:BAX) Upcoming US$0.28 Dividend - Yahoo Movies Canada
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 509 (M) |
| Shares Float | 505 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 92.4 (%) |
| Shares Short | 7,620 (K) |
| Shares Short P.Month | 8,130 (K) |
| EPS | -0.16 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.54 |
| Profit Margin | 17.9 % |
| Operating Margin | 12 % |
| Return on Assets (ttm) | 3.3 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 3.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 29.07 |
| EBITDA (p.s.) | 5.45 |
| Qtrly Earnings Growth | 33.7 % |
| Operating Cash Flow | 1,730 (M) |
| Levered Free Cash Flow | 1,700 (M) |
| PE Ratio | -273.47 |
| PEG Ratio | 3.3 |
| Price to Book value | 2.47 |
| Price to Sales | 1.41 |
| Price to Cash Flow | 12.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|